RNU6-1191P

Across TCGA pan-cancer cohorts, RNU6-1191P RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of RNU6-1191P’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where RNU6-1191P RNA is repressed in tumor relative to normal tissue. In most cancer types RNU6-1191P is over-expressed in tumor, although a few such as BRCA and PRAD show the opposite, repressed pattern.

BRCA, LUAD, and KIRP are the cancer types where RNU6-1191P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RNU6-1191P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	All	III,IV	−0.594	<.001	6	view →
LUAD	All	All	+0.241	<.001	6	view →
KIRP	All	III,IV	+0.340	.044	2	view →
PRAD	All	All	−0.265	.010	2	view →
LIHC	All	All	+0.135	.005	2	view →
THCA	All	All	−0.112	.003	2	view →
LUSC	Female	All	−0.186	.032	1	view →
COAD	All	All	−0.096	.029	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

RNU6-1191P–BRCA

Open the BRCA breakdown →